Five medications are FDA-approved for bipolar depression: quetiapine, lurasidone, lumateperone, cariprazine and the olanzapine-fluoxetine combination. Each is an atypical antipsychotic or includes one. Only quetiapine and lumateperone are approved for depression in bipolar II as well as bipolar I. No standard antidepressant is approved on its own for bipolar depression.
That short list surprises many people. When bipolar depression is mistaken for ordinary depression, the usual first step is an antidepressant, and that can backfire. This guide covers what each FDA label actually says, where lithium and other mood stabilizers fit, and what monitoring to expect. If you live in New Jersey or New York, Gimel Health offers bipolar disorder treatment in NJ with Michael Feldman, PA-C.
FDA-Approved Treatments for Bipolar Depression
Each medication below has an FDA-approved indication for the depressive phase of bipolar disorder. The details differ in ways that matter, such as which type of bipolar disorder is covered, which ages, and whether the drug can be added to lithium or valproate.
- Quetiapine (Seroquel, Seroquel XR): approved for “the acute treatment of depressive episodes associated with bipolar disorder”. The supporting trial enrolled adults with bipolar I or II. The extended-release label starts at 50 mg and reaches the recommended 300 mg a day by day 4.
- Lurasidone (Latuda, now also generic): approved for bipolar I depression on its own in adults and in children aged 10 to 17, and alongside lithium or valproate in adults. Its DailyMed label says to take it with food, at least 350 calories.
- Lumateperone (Caplyta): approved for depressive episodes of bipolar I or II in adults, on its own or with lithium or valproate, per its DailyMed label.
- Cariprazine (Vraylar): approved for bipolar I depression in adults. The label starts at 1.5 mg a day, with an option to rise to 3 mg on day 15.
- Olanzapine-fluoxetine (Symbyax): approved for acute depressive episodes in bipolar I. Its label covers patients aged 10 and older. This is the only approval that includes an antidepressant, and only in combination with olanzapine.
Being FDA-approved doesn’t mean a drug is right for everyone. A prescriber weighs your bipolar subtype, past responses, other medications, weight and metabolic health, and whether you can tolerate sedation.
Which Bipolar Depression Medication Covers Bipolar II?
If you have bipolar II, only two medications on the list have FDA approval for your depressive episodes: quetiapine, whose trial enrolled people with bipolar I or II, and lumateperone, whose label names both. Lurasidone, cariprazine and olanzapine-fluoxetine are approved for bipolar I depression only.
That’s also the honest answer to a common search, “the best antidepressant for bipolar 2”. No traditional antidepressant is FDA-approved for bipolar II depression. Prescribers sometimes use antidepressants carefully in bipolar II, but that’s a clinical judgment for each patient, not an approved indication.
Why Antidepressants Alone Can Be Risky
The main worry is that an antidepressant taken without a mood stabilizer can push someone with bipolar disorder toward hypomania, mania or a mixed state. The evidence for any added benefit is also weaker than many people expect. In 2007, the National Institute of Mental Health reported results from its STEP-BD program: a mood stabilizer alone appeared just as effective as a mood stabilizer plus an antidepressant for bipolar depression.
In the same program, patients with depression and some manic symptoms recovered no faster with an added antidepressant, and their manic symptoms were more severe three months later. The 2018 guidelines from CANMAT and the International Society for Bipolar Disorders (Yatham et al.) recommend against antidepressant monotherapy in bipolar I disorder.
Gimel Health has a separate post on antidepressants and bipolar disorder that covers when they are used and how risk is managed, so that detail isn’t repeated here.
Mood Stabilizers and Lithium
Lithium is still one of the core treatments for bipolar disorder, even though bipolar depression isn’t on its FDA label. Lithium’s DailyMed label covers bipolar I disorder: acute manic and mixed episodes, plus maintenance to help prevent future episodes. The CANMAT/ISBD guidelines list lithium among first-line options for both acute bipolar I depression and long-term maintenance.
Lamotrigine is another mood stabilizer often discussed for the depressive side of bipolar disorder. It’s FDA-approved for maintenance in bipolar I, not for treating an acute depressive episode, and it has to be started slowly to lower the risk of a serious rash. Valproate is mainly used for mania.
In practice, many people take more than one medication: a mood stabilizer for stability over time, plus one of the FDA-approved options during a depressive episode. Lurasidone and lumateperone are both approved for use alongside lithium or valproate.
Side Effects and Monitoring
All five FDA-approved medications carry boxed warnings covering two risks: increased mortality in elderly patients with dementia-related psychosis, and suicidal thoughts and behaviors in younger patients. The most common side effects differ by drug:
- Quetiapine XR: in the adult bipolar depression trial, drowsiness affected 52% of patients (13% on placebo) and dry mouth 37% (7% on placebo). Weight gain and metabolic changes are listed warnings.
- Lumateperone: drowsiness or sedation, dizziness, nausea and dry mouth.
- Cariprazine: nausea, restlessness, akathisia (an inner urge to keep moving) and other movement-related effects. The drug has a long half-life, so its label warns that side effects may first appear several weeks after starting.
- Lurasidone and olanzapine-fluoxetine: check each label with your prescriber. Weight and metabolic effects are a particular consideration with olanzapine.
Monitoring usually includes weight, blood sugar and cholesterol for the antipsychotics, plus regular questions about mood, sleep and any signs of hypomania. Lithium needs blood tests. Its label calls for serum lithium levels starting after 3 days and repeated until you’re stable, kidney checks before and during treatment, and thyroid tests before starting, at 3 months, and every 6 to 12 months after that.
If bipolar depression brings thoughts of suicide, don’t wait for your next appointment. Call or text the 988 Suicide & Crisis Lifeline, or call 911.
How Long Does Bipolar Depression Medication Take to Work?
Expect to wait weeks rather than days. The clinical trials behind these approvals measured results over roughly 6 to 8 weeks; the quetiapine XR bipolar depression trial ran for 8 weeks. Some people notice better sleep or less anxiety earlier, but the improvement in mood usually builds over that period.
Several medications also need time to reach their target dose. Quetiapine XR gets there within days, while cariprazine’s dose changes take weeks to show fully. Lithium is adjusted by blood levels, so the first month often involves several check-ins. If a medication hasn’t helped after an adequate trial at the right dose, that’s useful information. It doesn’t mean nothing will work.
Getting Care in NJ or NY
Bipolar depression is often first treated as ordinary depression, which is why the evaluation matters as much as the prescription. A first visit looks at your mood history, including any past periods of unusually high energy or little need for sleep, along with family history, current medications and other conditions. ADHD is one that overlaps, covered in how clinicians tell ADHD and bipolar disorder apart. The post on your first psychiatric evaluation explains what that visit involves.
Michael Feldman, PA-C, treats adults, adolescents and children who live in New Jersey or New York. He sees patients at 440 West St, Suite 307, Fort Lee, and many visits can be done by telehealth. The initial evaluation is $350 for up to 50 minutes, and follow-ups are $300 for up to 25 minutes. A free discovery call of about 10 minutes comes first. Care is self-pay, a superbill is provided, and how much your insurer reimburses depends on your plan. Appointments are typically available within 1 to 2 weeks, in English, Russian or Hebrew.
Live in NJ or NY? Book an evaluation for bipolar disorder treatment with Michael Feldman, PA-C, starting with a free 10-minute discovery call.
Outside NJ and NY? Michael can only treat patients located in those two states. A local psychiatric clinician or your primary care provider is the right next step, and FindTreatment.gov lists mental health providers by location.
